Table 1.
Patients’ characteristics (N = 223).
| Total N = 223 |
Sotrovimab N = 114 |
Tixagevimab/ cilgavimab N = 50 |
Nirmatrelvir/ritonavir N = 49 |
Remdesivir N = 10 |
p-value | |
|---|---|---|---|---|---|---|
| Age (years); median (IQR) | 59 (42; 68) | 55 (40.25; 67.75) | 60 (49; 66) | 66.5 (47.5; 73.5) | 63 (45.2; 67.5) | 0.15 |
| Sex | ||||||
| M; n (%) | 124 (56) | 64 (56) | 24 (48) | 28 (57) | 8 (80) | 0.31 |
| F; n (%) | 99 (44) | 50 (44) | 26 (52) | 21 (43) | 2 (20) | – |
| BMI, median (IQR) | 24.8 (21.5; 28) | 24.9 (21.6; 29.6) | 24.7 (21.4; 26.7) | 24.3 (22.8; 27.7) | 25.3 (22.3; 28;7) | 0.62 |
| Comorbidities | ||||||
| BMI > 30 kg/m2; n (%) | 38 (17) | 24 (21) | 6 (12) | 6 (12) | 2 (20) | 0.37 |
| Diabetes mellitus; n (%) | 44 (20) | 18 (16) | 15 (30) | 7 (14) | 4 (40) | 0.04 |
| Chronic heart failure; n (%) | 15 (7) | 8 (7) | 4 (8) | 3 (6) | 0 | 0.97 |
| Chronic respiratory failure; n (%) | 8 (4) | 3 (3) | 1 (2) | 4 (8) | 0 | 0.35 |
| GFR < 30 ml/min/1.73 m2; n (%) | 21 (9) | 10 (9) | 7 (14) | 2 (4) | 2 (20) | 0.2 |
| End-stage kidney disease with dialysis; n (%) | 4 (2) | 2 (2) | 2 (4) | 0 (0) | 0 | 0.6 |
| Causes of immunosuppression | ||||||
| Solid organ transplantation; n (%) | 81a (36) | 41a (35) | 34a (68) | 0 (0) | 6 (60) | < 0.001 |
| Kidney; n (%) | 25a (11) | 19a (17) | 5a (10) | 0 (0) | 1 (10) | – |
| Heart; n (%) | 21a (9) | 12a (11) | 4 (8) | 0 (0) | 5 (50) | – |
| Liver; n (%) | 14 (6) | 5 (4) | 9 (18) | 0 (0) | 0 (0) | – |
| Lung; n (%) | 17 (8) | 4 (4) | 13 (26) | 0 (0) | 0 (0) | – |
| Multiorgan; n (%) | 4 (2) | 1 (1) | 3 (6) | 0 (0) | 0 (0) | – |
| Anti-CD20 therapy; n (%) | 59a (27) | 32a (28) | 9 (18) | 16 (32) | 2 (20) | 0.38 |
| Anti-CD20 based chemotherapy for haematological malignancy; n (%) | 25a (11) | 9a (8) | 3 (6) | 11 (22) | 2 (20) | 0.02 |
| Anti-CD20 for multiple sclerosis; n (%) | 20 (9) | 17 (15) | 1 (2) | 2 (4) | 0 (0) | 0.02 |
| Anti-CD20 for autoimmune diseaseb; n (%) | 11 (5) | 5 (4) | 3 (6) | 3 (6) | 0 (0) | 0.86 |
| Anti-CD20 for solid organ transplantation; n (%) | 3a (1) | 1a (1) | 2a (2) | 0 | 0 (0) | 0.36 |
| Chemotherapy for haematological malignancy without anti-CD20 therapy; n (%) | 32 (14) | 18 (16) | 4 (8) | 9 (18) | 1 (10) | 0.46 |
| Chemotherapy for solid cancer; n (%) | 19 (9) | 9 (8) | 1 (2) | 9 (18) | 0 (0) | 0.03 |
| Allogenic stem cell transplantation; n (%) | 16 (7) | 5 (4) | 3 (6) | 7 (14) | 1 (10) | 0.12 |
| Other; n (%) | 20 (9) | 11 (10) | 1 (2) | 8 (16) | 0 (0) | 0.06 |
| Vaccination status | ||||||
| Fully vaccinated; n (%) | 167 (75) | 91 (79) | 39 (78) | 30 (61) | 8 (80) | 0.17 |
| Not fully vaccinated; n (%) | 12 (5) | 7 (6) | 0 (0) | 5 (10) | 0 (0) | – |
| Unvaccinated; n (%) | 6 (3) | 3 (3) | 0 (0) | 3 (6) | 0 (0) | – |
| Vaccination status unknown; n (%) | 37 (16) | 13 (11) | 11 (22) | 11 (22) | 2 (20) | – |
| Seropositive; n (%) | 86 (36) | 45 (39) | 26 (52) | 14 (29) | 1 (10) | < 0.001 |
| Seronegative; n (%) | 35 (16) | 27 (24) | 5 (10) | 0 (0) | 2 (20) | – |
| Serologic status unknown; n (%) | 73 (32) | 34 (30) | 14 (28) | 23 (47) | 2 (20) | – |
| Serologic status uninterpretable; n (%) | 29 (13) | 8 (7) | 5 (10) | 12 (24) | 4 (40) | – |
| IgG anti-spike (BAU/mL); median (IQR) | 156 (0; 726) | 49.5 (0; 324.75) | 188 (75.5; 1067.5) | 1162 (381; 2875) | 0 (0; 136) | < 0.001 |
| IgG anti-spike < 264 BAU/mL; n (%) | 76 (34) | 52 (46) | 19 (38) | 3 (6) | 2 (20) | < 0.001 |
| Pre-exposure prophylaxis with monoclonal antibodies within 6 months | ||||||
| Yes; n (%) | 29 (13) | 8 (7) | 5 (10) | 12 (24) | 4 (40) | < 0.001 |
| Tixagevimab/cilgavimab; n (%) | 26 (12) | 5 (3) | 5 (10) | 12 (24) | 4 (40) | – |
| Casirivimab/imdevimab; n (%) | 3 (1) | 3 (3) | 0 (0) | 0 (0) | 0 (0) | – |
| No; n (%) | 194 (87) | 106 (93) | 45 (90) | 37 (76) | 6 (60) | – |
| Variant | ||||||
| Omicron; n (%) | 140 (63) | 79 (69) | 36 (72) | 18 (37) | 7 (70) | < 0.001 |
| Non-Omicron; n (%) | 2 (1) | 0 | 0 | 0 | 2 (10) | – |
| Unknown; n (%) | 82 (36) | 35 (31) | 14 (28) | 31 (63) | 1 (10) | – |
| Clinical status | ||||||
| Symptomatic | 187 (84) | 98 (86) | 41 (82) | 38 (78) | 10 (100) | 0.31 |
| Asymptomatic | 36 (15) | 16 (14) | 9 (18) | 11 (22) | 0 (0) | – |
aTwo SOT recipients in the sotrovimab group and two in the tixagevimab/cilgavimab group were also receiving an anti-CD20 therapy.
bWegener's granulomatosis (n = 1), auto-immune cerebellitis (n = 1), neuromyelitis optica (n = 2), chronic polyradiculoneuropathy (n = 1), Lewis-Sumner syndrome (n = 1), ANCA-associated vasculitis (n = 1); glomerulonephritis (n = 1), microscopic polyangiitis (n = 1), idiopathic thrombocytopenic purpura (n = 1) and systemic lupus erythematosus (n = 1).
Significant values are in bold.